Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity : vimarsana.com

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event Compared to Placebo – – NEXLETOL Demonstrated Clinical Benefit in...

Related Keywords

Alexis Callahan , Tiffany Aldrich , Leslie Cho , Joanne Foody , Fatima Rodriguez , Journal Of The American College Cardiology , Exchange Commission , American College Of Cardiology , University Of Louisville School Medicine , Esperion Therapeutics Inc , Atherosclerosis Research Center , Globenewswire Inc , American College Of Cardiology Annual Scientific Sessions , Patients With Obesity Who Took , Less Likely , Major Adverse Cardiovascular Event , Clinical Benefit , Historically Underrepresented Groups , Latinx Patients With , Without Cardiovascular Disease , Sets New Standards , Latinx Patients , Annual Scientific Sessions , Anne Foody , Chief Medical Officer , Louisville School , Cardiovascular Events , Subset Analysis , Stanford Medicine , Latinx Participants , Statin Intolerance Receiving Bempedoic Acid , Pre Specified Subgroup Analysis , American College , Statin Intolerant Women Receiving Bempedoic Acid , Adverse Event , Contact Information , Markets ,